Sedor Pharmaceuticals NDA for CE-Fosphenytoin for Status Epilepticus Receives PDUFA Date

Sedor Pharmaceuticals NDA for CE-Fosphenytoin for Status Epilepticus Receives PDUFA Date Potential significant advance for life threatening condition   July 30, 2018, 10:00 AM Eastern Standard Time   PAOLI, Pa., –(BUSINESS WIRE)— Sedor Pharmaceuticals, LLC (Sedor) announced that the US FDA accepted its 505(b)2 NDA (210864) for Sedor’s lead program, IM/IV Captisol-Enabled™ (CE) Fosphenytoin,(fosphenytoin sodium […]